Who makes Prasugrel based short DAPT?

Prasugrel based short DAPT is developed by Research Maatschap Cardiologen Rotterdam Zuid.

What development phase is Prasugrel based short DAPT in?

Prasugrel based short DAPT is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Prasugrel based short DAPT

Research Maatschap Cardiologen Rotterdam Zuid · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Prasugrel based short DAPT
Sponsor	Research Maatschap Cardiologen Rotterdam Zuid
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Prasugrel based short DAPT CI brief — competitive landscape report
Prasugrel based short DAPT updates RSS · CI watch RSS
Research Maatschap Cardiologen Rotterdam Zuid portfolio CI